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Abstract
Background: The prostate cancer prevention trial (PCPT) and Reduction by dutasteride of Prostate Cancer Events
(REDUCE) trial found that 5α-reductase (5αR) inhibitors finasteride and dutasteride respectively, decreased prostate
cancer prevalence but also increased the incidence of high-grade tumors. 5αR2 is the main isoenzyme in normal
prostate tissue; however, most prostate tumors have high 5αR1 and low 5αR2 expression. Because finasteride
inhibits only 5αR2, we hypothesized that it would not be as efficacious in preventing prostate cancer development
and/or progression in C57BL/6 TRAMP x FVB mice as dutasteride, which inhibits both 5αR1 and 5αR2.
Method/Principal Findings: Six-week-old C57BL/6 TRAMP x FVB male mice were randomized to AIN93G control
or pre- and post- finasteride and dutasteride diet (83.3 mg drug/kg diet) groups (n =30–33) that began at 6 and 12
weeks of age, respectively, and were terminated at 20 weeks of age. The pre- and post- finasteride and dutasteride
groups were designed to test the preventive and therapeutic efficacy of the drugs, respectively. Final body weights,
genitourinary tract weights, and genitourinary tract weights as percentage of body weights were significantly
decreased in the Pre- and Post-dutasteride groups compared with the control. The Post-dutasteride group showed
the greatest inhibition of prostatic intraepithelial neoplasia progression and prostate cancer development.
Surprisingly, the Post-dutasteride group showed improved outcomes compared with the Pre-dutasteride group, which
had increased incidence of high-grade carcinoma as the most common and most severe lesions in a majority of
prostate lobes. Consistent with our hypothesis, we found little benefit from the finasteride diets, and they increased
the incidence of high-grade carcinoma.
Conclusion: Our findings have commonalities with previously reported PCPT, REDUCE, and the Reduction by
dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial results. Our results may
support the therapeutic use of dutasteride, but not finasteride, for therapeutic or preventive use.
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Introduction
Prostate cancer is the most commonly diagnosed non-skin
neoplasm in men and is projected to account for 28% of US
male cancer cases in 2013 [1]. Most prostate tumor growth is
initially androgen-dependent or androgen-sensitive [2]. The
main circulating androgen, testosterone, is converted to
dihydrotestosterone by the isoenzymes 5α-reductase 1 and 5α-
reductase 2. Dihydrotestosterone has up to a ten-fold higher
affinity to the androgen receptor than testosterone, making it a
more potent androgen [3,4]. 5α-reductase 2 is the major
isoenzyme in the prostate [5]; however, multiple [6-9], but not
all [10-12], studies have reported increased 5α-reductase 1
and/or decreased 5α-reductase 2 mRNA expression or activity
in prostate cancer compared with nonmalignant prostate tissue.
Furthermore, 5α-reductase 1 and 5α-reductase 2 were found in
73% and 56%, respectively, of human prostate cancer tissues
[11].
Finasteride (5α-reductase 2 inhibitor) and dutasteride (5α-
reductase 1 and 2 inhibitor) are commonly used to treat benign
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prostatic hyperplasia (BPH), a nonmalignant enlargement of
the prostate. The potential of these inhibitors to decrease
prostate cancer development and/or progression through their
anti-androgen action has been examined in several clinical
trials. The Prostate Cancer Prevention Trial (PCPT) and the
Reduction by Dutasteride of Prostate Cancer Events
(REDUCE) trial found that finasteride and dutasteride
decreased prostate cancer risk by 24.8% and 23%,
respectively, but both inhibitors also increased the risk of
developing high-grade prostate cancer [13,14]. As a result, the
Food and Drug Administration (FDA) amended the safety
information for both drugs to state that they increase high-
grade prostate cancer in patients [15]. In addition, it has been
projected that finasteride and dutasteride in PCPT and
REDUCE trials respectively showed no prostate cancer
mortality benefit [16]. Another clinical trial, the Reduction by
Dutasteride of Clinical Progression Events in Expectant
Management (REDEEM) trial found that dutasteride
significantly delayed prostate cancer progression with no
reported adverse events in men with low-risk, localized
prostate cancer [17].
In animal models, dutasteride, but not finasteride, decreased
Dunning R-3327H rat prostate tumor weights [18]. Similarly,
Canene-Adams and colleagues also reported that finasteride
did not alter Dunning R-3327H rat prostate tumor areas or
weights despite reducing androgen-sensitive tissue weights
[19]. Finasteride also did not decrease prostatic intraepithelial
neoplasia (PIN) or adenocarcinoma in 10-week-old transgenic
rats bearing the probasin/simian virus 40 T antigen (SV40 Tag)
construct but did decrease lesion size in lateral and ventral
lobes, but not the dorsal lobe, of the prostate [20]. Both
finasteride and dutasteride were effective in reducing LNCaP
human prostate cancer xenograft growth in male nude mice
[18]. Dutasteride significantly decreased LuCaP 35 tumor
growth in Balb/c mice [21]. Previously, we examined the effects
of finasteride and dutasteride diets begun 1-2 weeks before or
3 weeks after subcutaneous injection of WPE1-NA22 human
prostate cancer cells in male nude mice, but we were unable to
answer our research question due to poor tumor growth [22].
Thus, we decided to determine the effects of finasteride and
dutasteride in transgenic adenocarcinoma of the mouse
prostate (TRAMP) mice since prostate cancer development
and progression have been well characterized in this model
[23]. TRAMP mice prostate cancer is promoted by the
expression of the SV40 large and small T antigen and
undergoes progressive stages of cancer development starting
from prostatic intraepithelial neoplasia (PIN) to
adenocarcinoma and metastasis [24,25]. In this study, we
compared the effects of finasteride- or dutasteride-containing
diets begun at 6 weeks or 12 weeks of age on prostate tumor
development in C57BL/6 TRAMP x FVB mice. These time
points were chosen because 6 weeks is when the mice reach
sexual maturity and develop pathologic features similar to low-
grade PIN [26]. This would allow us to determine whether
finasteride and/or dutasteride can inhibit PIN progression and
prostate cancer development. The post- finasteride and
dutasteride diets began at 12 weeks of age when mice are
expected to have developed PIN and well-differentiated
prostate cancer [25]. Beginning diets at this age would allow us
to determine whether therapeutic finasteride and/or dutasteride
can inhibit PIN and/or prostate cancer progression. Because of
the increase in 5α-reductase 1 and decrease in 5α-reductase 2
activity and expression that may occur during prostate cancer
development, we hypothesized that finasteride diets begun at
either time point would not and dutasteride diets begun at
either time point would significantly inhibit prostate cancer
development and/or progression.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee (IACUC)
at Kansas State University approved all animal procedures
(protocol 2969).
Study Mice, Diets, and Design
Six-week-old heterozygous C57BL/6-Tg 8247Ng/J TRAMP
male and female mice were purchased (The Jackson
Laboratory, Bar Harbor, ME) and bred to produce homozygous
males. These were bred with female FVB/NJ mice (The
Jackson Laboratory, Bar Harbor, ME) to produce C57BL/6
TRAMP x FVB mice. Male C57BL/6 TRAMP x FVB mice were
weaned and began consuming the control diet at 3 weeks of
age before being randomized into Control, Pre-Finasteride,
Post-Finasteride, Pre-Dutasteride, and Post-Dutasteride
groups (n = 30–33) at 6 weeks of age. Mice were individually
housed, monitored daily, weighed weekly, and provided diets
and water ad libitum. AIN93-G treatment diets (Research Diets,
New Brunswick, NJ) contained dutasteride (kindly donated by
GlaxoSmithKline Pharmaceuticals, Research Triangle Park,
NC) and finasteride (Kemprotec, Middlesbrough, UK) at 83.3
mg/kg of diet, the same dose used in our previous study [22].
These diets were designed to provide ~10mg drug/kg body
weight, which was the midrange dutasteride dose provided by
Xu and colleagues [18]. Pre- and post-groups began their
treatment diets at 6 weeks and 12 weeks of age, respectively
(Figure 1). Seven mice did not complete the study for health
reasons unrelated to tumor growth, leaving the group numbers
shown in Figure 1. At 20 weeks of age, mice were anesthetized
by CO2 inhalation and euthanized by exsanguination. The
genitourinary tracts, kidneys, and lungs were dissected, and
the genitourinary tracts were weighed. Iliac lymph nodes were
also collected whenever possible. All tissues were fixed by
immersion in 10% neutral buffered formalin for 48 hours, and
then moved to 70% alcohol until processing in the Kansas
State University Veterinary Diagnostic Laboratory.
Histopathology
The seminal vesicles; anterior, dorsal, lateral, and ventral
prostate lobes; ampulla; urinary bladder; and proximal urethra
were sampled as one tissue. Orientation was maintained, and
the dorsal side was placed down in the cassette for histology
processing first. In mice with prostate tumors, distinct prostate
lobes were not recognizable, so a section was taken through
the center of the mass. Tissues were routinely processed and
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embedded in paraffin wax. Sections were made at 4 µm,
routinely processed, and stained with hematoxylin and eosin.
After the dorsal sections were processed, the blocks were
melted down and the tissue was flipped and re-embedded for
examination of the ventral prostate. Prostate lesions were
scored blindly twice by a board-certified veterinary pathologist
(JNH) according to a previously described grading scheme
[27]. In short, both the most common and most severe lesions
were graded separately, and then adjusted for distribution. If a
neoplasm replaced all four prostate lobes, then all lobes
received the same score. Select tissues were also blindly
scored twice by a second board-certified veterinary pathologist
(APB) to ensure scoring consistency. Iliac lymph nodes were
examined for metastasis by removal of the kidneys and
sublumbar tissue; histological processing was identical to the
prostatic tissue. Photomicrographs were taken with an
Olympus DP26 digital camera (Olympus America, Center
Valley, PA) with a 40X objective, giving 0.75µm resolution.
 Images were captured with Olympus cellSens software.
Statistical Analysis
Data were analyzed using SAS 9.3 (SAS Institute Inc., Cary,
NC) with p<0.05 considered statistically significant. Natural logs
were used to transform data that did not meet model
assumptions. Data were analyzed using ANOVA with Fisher’s
Least Significant Difference (LSD). Iliac lymph node
metastases incidence was analyzed using the Kruskal Wallis
non-parametric one-way ANOVA.
Results
Final body weights and genitourinary tract weights
Pre- and Post-Dutasteride groups’ final body weights were
significantly decreased compared with the control despite no
significant difference in daily food intake (Table 1); however,
both dutasteride diets significantly decreased the weight gain/
food intake ratio versus the control and Pre-Finasteride group.
While it is a small numerical difference, the Pre-Finasteride
group’s daily food intake was significantly higher than the
control and both dutasteride groups. Genitourinary tract
weights for Pre- and Post-Dutasteride groups also were
significantly lower than the control (Table 1 and Figure 2).
Figure 1.  Study design.  Male C57BL/6 TRAMP x FVB mice were weaned at 3 weeks of age, fed a control diet, and randomized
into Control, Pre-Finasteride, Post-Finasteride, Pre-Dutasteride, and Post-Dutasteride groups (n = 30–33) at 6 weeks of age. Pre-
and post-groups began their treatment diets at 6 and 12 weeks, respectively, and the study was terminated when mice were 20
weeks of age.
doi: 10.1371/journal.pone.0077738.g001
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Genitourinary tract weights as percentage of body weights in
the Pre- and Post-Dutasteride groups were also significantly
lower than the control and Post-Finasteride group; thus the
significant decrease in genitourinary tract weights was not due
to the decreased body weights in these groups. Both
dutasteride groups’ genitourinary tract weights were
significantly decreased compared with the Post-Finasteride
group; the Pre-Dutasteride group’s genitourinary tract weights
and genitourinary tract weights as percentage of body weights
were also significantly decreased compared with the Pre-
Finasteride group. The Pre-Finasteride group’s genitourinary
tract weights as percentage of body weights also were
significantly decreased compared with the control.
Most severe lesion scores
The raw and adjusted mean most severe lesion scores for
the anterior, dorsal, and lateral lobes were significantly
decreased in the Post-Dutasteride group versus the control
(Table 2). Representative images of the different pathological
grades used in the grading scheme are shown in Figure 3. The
adjusted mean most severe lesion score was also significantly
decreased for the ventral lobe of the Post-Dutasteride group
compared with the control. The raw and adjusted mean most
severe lesion scores for the anterior and dorsal lobes of the
Post-Dutasteride groups were also significantly decreased
compared with the finasteride groups. The raw and adjusted
mean most severe lesion scores for the anterior and dorsal
Table 1. Final body weights, daily food intake, weight gain/food intake ratio, genitourinary tract weights, and genitourinary
tract weights as percentage of body weights (n = 28-33)1
Group Final body weights (g) Daily food intake (g)
Weight gain/food intake ratio (g
gained/g total food intake x
100)
Genitourinary tract weights
(g)
Genitourinary tract weights as
percentage of body weights
Control 33.3 ± 0.5a 2.99 ± 0.03a 2.8 ± 0.2a 1.56 ± 0.46a 4.91 ± 1.51a
Pre-Finasteride 33.7 ± 0.6a 3.08 ± 0.02b 2.8 ± 0.2a 1.31 ± 0.55a,b 3.50 ± 1.32b,d
Post-Finasteride 33.0 ± 0.6a,b 3.02 ± 0.04a,b 2.7 ± 0.2a,b 1.65 ± 0.55a 4.87 ± 1.55a,b
Pre-Dutasteride 29.9 ± 0.4c 2.96 ± 0.02a 1.6 ± 0.1c 0.35 ± 0.09c 1.19 ± 0.31c
Post-Dutasteride 31.8 ± 0.5b 2.96 ± 0.02a 2.4 ± 0.1b 0.59 ± 0.20b,c 1.88 ± 0.63c,d
1 Data are mean ± SEM; values with different letters are statistically different (p<0.05).
doi: 10.1371/journal.pone.0077738.t001
Figure 2.  Genitourinary tract weights.  Solid lines indicate mean values (n = 30–33).
Pre-F = Pre-Finasteride, Post-F = Post-Finasteride, Pre-D = Pre-Dutasteride, Post-D = Post-Dutasteride.
doi: 10.1371/journal.pone.0077738.g002
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lobes of the Pre-Dutasteride group were significantly
decreased versus the control. The lateral lobe adjusted mean
most severe lesion score was also significantly decreased in
the Pre-Dutasteride group compared with the control. There
were also no significant differences in raw and adjusted mean
most severe lesion scores between the finasteride groups and
the control.
Most common lesion scores
The raw mean most common lesion scores for the anterior
and dorsal lobes were significantly decreased in both
dutasteride groups versus the control (Table 3). In addition, for
all lobes in the Post-Dutasteride group, the adjusted most
common lesion scores were significantly decreased compared
with the control. The adjusted most common lesion scores for
the anterior, dorsal, and lateral lobes in the Pre-Dutasteride
group were significantly decreased versus the control. The
Post-Dutasteride group anterior lobe raw and adjusted mean
most common lesion scores and both dutasteride groups’
dorsal lobe adjusted most common lesion scores were
significantly decreased compared with the Post-Finasteride
group. The adjusted most common lesion score for the dorsal
lobe in the Pre-Finasteride group was significantly decreased
versus the control, despite being numerically higher.
Transforming the data so that it would meet assumptions
resulted in a transformed adjusted mean score that was
significantly lower than the control because the transformed
score was not as impacted by the high scores in this group.
Table 2. Raw and adjusted mean most severe lesion scores for the anterior, dorsal, lateral, and ventral prostate lobes (n =
28–33)
 Anterior prostate Dorsal prostate Lateral prostate Ventral prostate
Group Raw Adjusted Raw Adjusted Raw Adjusted Raw Adjusted
Control 3.36 ± 0.30a 8.69 ± 0.99a 3.56 ± 0.28a 9.52 ± 0.86a 3.45 ± 0.34a 9.45 ± 1.05a 3.03 ± 0.36 8.05 ± 1.13a
Pre-Finasteride 3.20 ± 0.38a 8.92 ± 1.26a 3.31 ± 0.44a,b 8.74 ± 1.43a,b 3.37 ± 0.45a,b 9.05 ± 1.46a,b 3.53 ± 0.49 9.55 ± 1.58a,b
Post-Finasteride 3.03 ± 0.36a 7.69 ± 1.15a 3.47 ± 0.37a,b 9.24 ± 1.20a 3.32 ± 0.46a,b 8.98 ± 1.46a,b 3.26 ± 0.42 8.73 ± 1.35a,c
Pre-Dutasteride 2.09 ± 0.30b 4.84 ± 0.95b 3.06 ± 0.45b,c 8.03 ± 1.4b,c 3.25 ± 0.47a,b 8.52 ± 1.48b 3.11 ± 0.47 8.05 ± 1.54a,b
Post-Dutasteride 2.21 ± 0.26b 5.09 ± 0.82b 2.23 ± 0.33c 5.53 ± 1.04c 2.86 ± 0.43b 7.35 ± 1.34b 2.53 ± 0.40 6.27 ± 1.28b
1. Data are mean ± SEM; values with different letters are statistically different (p<0.05).
doi: 10.1371/journal.pone.0077738.t002
Figure 3.  Prostate pathology in 20-week-old C57BL/6 TRAMP x FVB male mice captured at 40X magnification.  (A) Grade 1,
low-grade PIN. There is focal hyperplasia of prostate epithelial cells resulting in stratification of cells (arrow). Hyperplastic cells have
increased basophilia and increased nuclear to cytoplasmic ratios. (B) Grade 2, moderate-grade PIN. Hyperplastic epithelial cells
form increased numbers of short and tall papillary projections that extend into the glandular lumen. (C) Grade 3, high-grade PIN.
There is loss of prostate glandular lumina due to the presence of numerous hyperplastic prostate epithelial cells that project into the
lumen and form a cribiform pattern. Hyperplastic cells do not invade the connective tissue that separates the glands into distinct
lobules (arrows). (D) Grade 5, Well-differentiated adenocarcinoma. Well-differentiated neoplastic cells form tubular or glandular like
structures that have obliterated lobular architecture by invasion of the connective tissue borders; lobules cannot be observed in this
photomicrograph as compared to photomicrograph C. Necrosis of neoplastic cells is absent. (E) Grade 6, Moderately-differentiated
adenocarcinoma. Neoplastic prostate epithelial cells are attempting to form glandular structures. Glandular structures vary in size
and shape. Cellular atypia is increased and necrosis is present (asterisks). (F) Grade 7, Poorly-differentiated carcinoma. Neoplastic
cells have marked atypia and are arranged in sheets with no attempt at forming glandular or tubular structures as compared to
figures D and E.
doi: 10.1371/journal.pone.0077738.g003
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Most severe lesion histopathological distribution
Low-grade (LG) and high-grade (HG) PIN incidence as the
most severe lesion increased and decreased, respectively,
significantly in all lobes in both dutasteride groups versus the
control (Table 4). Low-grade PIN incidence was increased in
the ventral lobe of both finasteride groups compared with the
control. Lateral and ventral lobe medium-grade (MG)-PIN
incidence was also significantly decreased in both dutasteride
groups versus the control. Compared with the control, there
was a significant increase in MG-PIN incidence in the dorsal
lobe of the Pre-Finasteride group. Well-differentiated (WD)
adenocarcinoma incidence in the anterior lobe was significantly
decreased in both finasteride and dutasteride groups compared
with the control, and the Pre-Finasteride group had significantly
increased moderately differentiated (MD) adenocarcinoma
incidence versus the control in the ventral lobe. These
differences are, however, based on low incidence levels. The
finasteride groups and the Pre-Dutasteride group had
significantly increased poorly differentiated (PD) carcinoma and
prostate cancer (WD-PD) incidence in the lateral and ventral
lobes versus the control. The finasteride groups and the Pre-
Dutasteride group also had increased poorly differentiated (PD)
carcinoma in the dorsal lobe versus the control. The Pre-
Finasteride and Pre-Dutasteride groups had increased prostate
cancer (WD-PD) incidence in the dorsal lobe versus the
control. The Post-Dutasteride group had significantly
decreased and increased PD carcinoma incidence in the
anterior and lateral lobes, respectively, compared with the
control. Both dutasteride groups had significantly decreased
prostate cancer (WD-PD) incidence in the anterior lobe
compared with the control.
Most common lesion histopathological distribution
As was observed in the most severe lesion scores, LG-PIN
as the most common lesion was significantly increased in all
lobes in both dutasteride groups versus the control (Table 5).
Both finasteride groups also had significantly increased LG-PIN
incidence in the dorsal, lateral, and ventral lobes compared
with the control. MG-PIN incidence was also significantly
decreased for the Pre-Finasteride group and both dutasteride
groups in the dorsal, ventral, and lateral lobes versus the
control. The Post-Finasteride group had significantly decreased
MG-PIN incidence in the ventral and lateral lobes compared
with the control. Both dutasteride groups had significantly
decreased incidence of HG-PIN versus the control in the
anterior, dorsal and lateral lobes. Both finasteride groups had
significantly decreased HG-PIN compared with the control in
the dorsal and lateral lobes. Both dutasteride groups had
significantly decreased incidence of PD carcinoma in the
anterior lobe versus the control. Both finasteride groups and
the Pre-Dutasteride group had significantly increased PD
carcinoma incidence compared with the control in the dorsal,
lateral, and ventral lobes. Compared with the control, a
significant increase in PD carcinoma incidence was observed
in the lateral prostate of the Post-Dutasteride group. Total
prostate cancer (WD-PD) was almost entirely composed of PD
carcinoma, so the significant differences compared with the
control were the same as those seen in PD carcinoma for the
anterior, dorsal and lateral lobes.
Iliac lymph node metastases
No significant differences were observed in the incidence of
iliac lymph node metastases between groups (Table 6);
however, a notable difference was found in incidence between
Post-Dutasteride (8%) and Post-Finasteride (29%) groups.
Discussion
Although the efficacy of finasteride and dutasteride in
inhibiting tumor growth has been compared, we believe we are
the first to determine the effectiveness of finasteride and
dutasteride on PIN progression and prostate cancer
development in C57BL/6 TRAMP x FVB mice. Overall, we
found that the Post-Dutasteride group had the greatest
decrease in PIN progression and prostate cancer development.
Although not significant, we observed the lowest level of lymph
node metastases in this group. We unexpectedly found that the
Post-Dutasteride group had better outcomes than the Pre-
Dutasteride group, primarily as a result of the higher incidence
of PD carcinoma in most lobes in the Pre-Dutasteride group.
Both finasteride groups had decreased incidence of HG-PIN,
but not to the extent seen in the dutasteride groups. The
finasteride groups also had increased incidence of poorly
differentiated prostate cancer in most lobes.
Our findings are similar to results in other animal models that
found finasteride failed to inhibit prostate cancer progression
Table 3. Raw and adjusted mean most common lesion scores for the anterior, dorsal, lateral, and ventral prostate lobes (n =
28–33)
 Anterior prostate Dorsal prostate Lateral prostate Ventral prostate
Group Raw Adjusted Raw Adjusted Raw Adjusted Raw Adjusted
Control 2.55 ± 0.36a 6.75 ± 1.15a 2.63 ± 0.23a 7.41 ± 0.69a 2.62 ± 0.32 7.42 ± 1.01a 2.72 ± 0.37 7.52 ± 1.19a  
Pre-Finasteride 2.38 ± 0.41a,b 6.23 ± 1.29a,b 2.74 ± 0.47a,b 7.43 ± 1.49b,c 2.82 ± 0.47 7.70 ± 1.50a,b 3.16 ± 0.50 8.64 ± 1.62a,b  
Post-Finasteride 2.33 ± 0.38a,c 6.00 ± 1.19a,c 2.82 ± 0.42a,b 7.53 ± 1.26a,b 2.88 ± 0.47 7.95 ± 1.48a,b 2.95 ± 0.44 8.11 ± 1.41a
Pre-Dutasteride 1.63 ± 0.27b,c 3.72 ± 0.85b,c 2.32 ± 0.43b 6.06 ± 1.37c 2.69 ± 0.46 7.02 ± 1.44b 2.73 ± 0.46 7.06 ± 1.48a,b  
Post-Dutasteride 1.59 ± 0.27b 3.68 ± 0.83b 2.03 ± 0.33b 5.08 ± 1.06c 2.33 ± 0.40 5.95 ± 1.27b 2.28 ± 0.41 5.72 ± 1.30b  
1. Data are mean ± SEM; values with different letters are statistically different (p<0.05).
doi: 10.1371/journal.pone.0077738.t003
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[20] or tumor growth [18,19] and dutasteride decreased
prostate tumor growth [18]. We found the weakest response to
dutasteride in the ventral lobe. Another study that used the
same scoring system also found fewer statistical differences in
the ventral lobe in response to tomato powder and soy germ
diets, especially compared with the dorsal and lateral lobes
[28]. This decrease in efficacy in the ventral lobe might be
explained by the fact that in large probasin-large T antigen
mice, dutasteride markedly decreased the dorsolateral prostate
weights but had little to no effect on ventral prostate weights
[29]. In addition, rat ventral prostate has almost two-fold higher
concentrations of testosterone and dihydrotestosterone than
the dorsolateral prostate; furthermore, after finasteride
administration, ventral prostate lobe concentrations of
testosterone are almost twice as high as dorsolateral prostate
lobe concentrations [30]. Another possible explanation for
reduced sensitivity in the ventral prostate lobes is that the
transgene is expressed at much higher levels in the ventral
lobe [31].
We were surprised that both dutasteride groups had
decreased body weights and weight gain/food intake ratios
compared with the control. In our previous study, this diet had
no effect on body weights or weight gain/food intake ratios in
nude mice despite a longer feeding duration [22]. However,
dutasteride has decreased body weight or body weight gain in
other studies. For example, dutasteride administration at doses
of 2.5 and 5 mg/kg body weight to 8-week-old male Sprague–
Dawley rats for 2 weeks led to a significant decrease in their
body weights [32], and 4 or 8 weeks of infusion of 2 mg/kg
body weight dutasteride treatment led to a significant decrease
in body weight gain in large probasin-large T antigen
transgenic mice [29]. In our study, the mice were consuming ~8
mg/kg finasteride and dutasteride/day. This is obviously higher
than the concentration in previous studies. We did not find an
increase in body weights in the Pre-Finasteride group, unlike in
our previous study; however, there was a significant increase in
food intake versus the control. The lack of an increase in body
weights in the Pre-Finasteride group in this study supports our
belief that the significant increase in body weights in our
previous study was not due to the treatment diet [22].
In our previous study, both finasteride and dutasteride
decreased prostate and seminal vesicle weights as percentage
of body weights. Dutasteride also significantly decreased
seminal vesicle weights compared to finasteride [22]. In the
Table 4. Histopathological analysis (most severe lesion) of individual prostate lobes in control, finasteride, and dutasteride
groups
 PIN Adenocarcinoma Prostate cancer
 n LG MG HG WD MD PD (WD-PD)
Anterior prostate        
Control 32 2%a 30% 50%a 3% a 0% 16%a,b 19%a
Pre-Finasteride 30 15%a,b 32% 31%a,b 0%b 2% 20%a 22%a
Post-Finasteride 29 14%a 40% 28%a,b 0%b 0% 17%a 17%a
Pre-Dutasteride 32 49%c 35% 5%b 0%b 0% 11%b,c 11%b
Post-Dutasteride 33 33%b,c 48% 9%b 0%b 0% 9%c 9%b
Dorsal prostate        
Control 32 2%a 11%a 69%a 2% 2% 16%a 19%a,c
Pre-Finasteride 29 17%a 45%b 10%b,c 0% 0% 28%b 28%b
Post-Finasteride 31 5%a 40%a,b 31%b 0% 0% 24%b 24%b,c
Pre-Dutasteride 31 42%b 26%a,b 3%c 0% 0% 29%b 29%b
Post-Dutasteride 33 43%b 38%a,b 6%c 0% 0% 12%a 12%a
Lateral prostate        
Control 28 11%a 46%a 23%a 0% 0% 20%a 20%a
Pre-Finasteride 30 23%a 43%a 2%b 0% 0% 32%b 32%b
Post-Finasteride 30 27%a,b 35%a,b 8%b 0% 0% 30%b,c 30%b,c
Pre-Dutasteride 32 42%b,c 22%b 3%b 0% 0% 33%b 33%b
Post-Dutasteride 33 48%c 20%b 6%b 0% 0% 26%c 26%c
Ventral prostate        
Control 30 0%a 35%a 45%a 0% 0%a 20%a 20%a
Pre-Finasteride 28 29%b 24%a,b,c 9%b 0% 4%b 35%b 38%b
Post-Finasteride 30 22%b 31%a,b 22%c 0% 0%a 25%c 25%c
Pre-Dutasteride 31 46%c 21%b,c 0%d 2% 0%a 31%b 33%d
Post-Dutasteride 30 51%c 13%c 15%b,c 0% 0%a 20%a 20%a
1. Values with different letters are statistically different from (p<0.05).
2. LG = low-grade, MG = moderate-grade, HG = high-grade, PIN = prostatic intraepithelial neoplasia, WD = well-differentiated,
MD = moderately differentiated, PD = poorly differentiated.
doi: 10.1371/journal.pone.0077738.t004
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current study, we think prostate tumor development is the
reason we did not find significant decreases in genitourinary
tract weights in the finasteride groups. The rates of lymph node
metastases found in this study are similar to those that have
been reported in 18-week-old [28] and 18–24-week-old
C57BL/6 TRAMP x FVB mice [33].
We are one of the first to use a new grading scheme for
TRAMP mice [27]. When comparing our results to those
reported previously, the most notable difference is that we had
a lower incidence of PD carcinoma as the most severe lesion
compared with 18-week-old C57BL/6 TRAMP x FVB mice [28]
and most severe and most common lesions in 18–24-week-old
C57BL/6 TRAMP x FVB mice [27]. Instead, we had much
higher incidence of PIN as the most severe and most common
lesions. Our average most severe lesion scores were also
lower than those for 10-week-old C57BL/6 TRAMP x FVB
mice, but the average most common lesion scores were similar
[27]. It is not clear why our scores were lower using this
grading scheme, but variation in the duration and severity of
prostate cancer in C57BL/6 TRAMP x FVB mice does exist.
Our interpretation of the grading scheme also could have led to
scores that were lower than previously reported results.
Table 5. Histopathological analysis (most common lesion) of individual prostate lobes in control, finasteride, and dutasteride
groups
 PIN Adenocarcinoma Prostate cancer
 n LG MG HG WD MD PD (WD-PD)
Anterior prostate        
Control 32 44%a 20% 20%a 0% 0% 16%a 16%a
Pre-Finasteride 30 56%a 22% 3%a,b 0% 0% 19%a 19%a
Post-Finasteride 29 50%a 29% 5%a,b 0% 0% 16%a 16%a
Pre-Dutasteride 32 76%b 16% 0%b 0% 0% 8%b 8%b
Post-Dutasteride 33 79%b 14% 0%b 0% 0% 8%b 8%b
Dorsal prostate        
Control 32 5%a 59%a 28%a 0% 0% 8%a 8%a
Pre-Finasteride 29 55%b 19%b,c 0%b 0% 0% 26%b 26%b
Post-Finasteride 31 33%c 44%a,d 2%b 0% 0% 21%b 21%b
Pre-Dutasteride 31 73%b 6%c 0%b 0% 0% 21%b 21%b
Post-Dutasteride 33 57%b 31%b,d 0%b 0% 0% 12%a 12%a
Lateral prostate        
Control 28 10%a 70%a 7%a 0% 0% 14%a 14%a
Pre-Finasteride 30 52%b 22%b 0%b 0% 0% 27%b 27%b
Post-Finasteride 30 47%b 25%b 2%b 0% 0% 27%b 27%b
Pre-Dutasteride 32 64%c 9%c 0%b 0% 0% 27%b 27%b
Post-Dutasteride 33 65%c 15%b,c 0%b 0% 0% 20%c 20%c
Ventral prostate        
Control 30 14%a 68%a 2% 0% 0% 16%a 16%a
Pre-Finasteride 28 45%b 20%b 0% 0% 0% 35%b 35%b
Post-Finasteride 30 32%c 43%c 0% 0% 0% 25%c 25%c,d
Pre-Dutasteride 31 69%d 2%d 0% 2% 0% 28%c 30%b,d
Post-Dutasteride 30 64%d 17%b 0% 0% 0% 19%a 19%a,c
1. Values with different subscript letters are statistically different from one another (p<0.05).
2. LG = low-grade, MG = moderate-grade, HG = high-grade, PIN = prostatic intraepithelial neoplasia, WD = well-differentiated,
MD = moderately differentiated, PD = poorly differentiated.
doi: 10.1371/journal.pone.0077738.t005
Table 6. Iliac lymph node metastases incidence in control, finasteride, and dutasteride groups.
Group n Lymph node metastases incidence (%)
Control 21 4 (19)
Pre-Finasteride 26 5 (19)
Post-Finasteride 24 7 (29)
Pre-Dutasteride 22 5 (23)
Post-Dutasteride 24 2 (8)
doi: 10.1371/journal.pone.0077738.t006
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However, we believe that our results from the scoring scheme
have given us tremendous insight into the effects of the
treatment diets on PIN progression and prostate cancer
development.
Interestingly, there are some similarities between our
findings and the outcomes from the finasteride and dutasteride
clinical trials. The Pre-Finasteride group was designed to be
similar to the participants of PCPT to determine whether
finasteride could prevent prostate cancer development. Our
findings were similar to PCPT; HG-PIN decreased and
incidence of PD carcinoma increased. It is important to note
that the effect of finasteride on progression to HG-PIN was
weaker than dutasteride. It has been suggested that decreased
prostate volume, biopsy density and/or prostate-specific
antigen (PSA) performance may have contributed to the
detection of more poorly differentiated prostate cancer in PCPT
men [34-38], but our findings support that the increased
incidence of high-grade prostate tumors seen in PCPT was an
adverse effect of finasteride treatment.
The Pre-Dutasteride group was designed to be similar to the
REDUCE trial, where the men who received dutasteride were
at high risk of developing prostate cancer. Our findings were
similar to the REDUCE trial in that the Pre-Dutasteride group
had reduced HG-PIN incidence but increased incidence of PD
carcinoma. The Post-Dutasteride group was designed to be
similar to the REDEEM trial, in which assigned men with low-
grade prostate cancer received dutasteride. Similar to the
REDEEM trial, in the Post-Dutasteride group, HG-PIN
incidence decreased without increasing the incidence of PD
carcinoma, except in the lateral prostate.
Some caveats about our study should be considered,
especially when interpreting what our findings might mean for
the use of these drugs in men. First, the drugs were
administered in diet, which differs from how most men take
them. Second, the body weight–scaled human oral dose [39] is
approximately 80 mg/day, which is much higher than the
dutasteride (0.5 mg/day) and finasteride (5 mg/day) doses that
most men take. In addition, the significant decrease in body
weights in the dutasteride groups might mean that dietary-
energy restriction might have contributed to the beneficial
effects seen in these groups.
In conclusion, our results suggest that the timing of
dutasteride treatment initiation may be critical to the risk of
developing PD carcinoma. Our results may support
therapeutic, but not preventive, use of dutasteride for this
reason. Our results do not support the therapeutic or
preventive use of finasteride. We plan to perform
immunohistochemistry on prostates from these mice to
elucidate why Post-Dutasteride treatment was effective and
why we found a discordant response in the Pre-Dutasteride
and both finasteride groups.
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